Liquidia (LQDA) Other financing activities (2020 - 2026)
Liquidia's (LQDA) quarterly Other financing activities came in at $1.8 million in Q1 2026, up 38.61% year-on-year from $1.3 million in Q1 2025, and up 87.38% quarter-over-quarter from $935000.0 in Q4 2025.
Liquidia (LQDA) Other financing activities (2020 - 2026) Analysis & Trends
Liquidia's Other financing activities history runs 7 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- On a quarterly basis, Other financing activities rose 38.61% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $5.3 million, a 96.19% decrease from a year earlier, with the FY2025 full-year figure at $4.8 million, down 96.52% from the prior year.
- Other financing activities grew to $1.8 million in Q1 2026 per LQDA's latest filing, from $935000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $135.6 million in Q4 2024 and bottomed at -$71.9 million in Q3 2024.
- The 5-year median for Other financing activities is $621000.0 (2022), against an average of $8.7 million.
- Across the five-year window, Other financing activities plunged 133512.5% in 2022 and soared 232290.62% in 2024, its largest moves.
- Year by year, Other financing activities stood at -$53.4 million in 2022, then surged by 100.15% to $80000.0 in 2023, then surged by 169428.75% to $135.6 million in 2024, then tumbled by 99.31% to $935000.0 in 2025, then soared by 87.38% to $1.8 million in 2026.
- Per Business Quant, the three latest LQDA Other financing activities figures stand at $1.8 million (Q1 2026), $935000.0 (Q4 2025), and $2.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.75 Mn |
| Mar 31, 2026 | 1.75 Mn |
| Dec 31, 2025 | 935,000.00 |
| Dec 31, 2025 | 935,000.00 |
| Sep 30, 2025 | 2.50 Mn |
| Sep 30, 2025 | 2.50 Mn |
| Jun 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 125,000.00 |
| Mar 31, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 135.62 Mn |
| Dec 31, 2024 | 135.62 Mn |
| Sep 30, 2024 | -71.94 Mn |
| Sep 30, 2024 | -71.94 Mn |
| Jun 30, 2024 | 74.37 Mn |
| Jun 30, 2024 | 74.37 Mn |
| Mar 31, 2024 | 503,000.00 |
| Mar 31, 2024 | 503,000.00 |
| Dec 31, 2023 | 80,000.00 |
| Dec 31, 2023 | 80,000.00 |